Introduction
============

Breast cancer is one of the most common and deadly female solid tumors ^[@ref-1]^. According to reports from Perou *et al*. ^[@ref-2]^, further confirmed by other investigators ^[@ref-3],\ [@ref-4]^, breast cancer is a highly molecularly heterogeneous disease. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment and, for instance, to reveal new targets for specific therapies. Recent studies based on original retrospective analysis of digitalis use in breast cancer patients have demonstrated the anticancer effect of cardiac glycosides ^[@ref-5]^ that directly inhibit Na ^+^/K ^+^-ATPase (NKA) activity. NKA signaling functions after interaction with cardiac glycosides were also shown ^[@ref-6]^. It seems rational that expression of NKA might influence breast cancer prognosis.

NKA is a significant integral membrane protein. NKA's main function is the creation and maintenance of electrochemical gradients for sodium and potassium ions in the living cell. These gradients have critical importance for control of cell volume, osmolarity and resting potential ^[@ref-7],\ [@ref-8]^. The minimal functional NKA consists of two associated alpha- and beta- subunits. The catalytic alpha-subunit is responsible for conversion of ATP energy to transport of Na ^+^ and K ^+^ across cell membranes and has ATP and cardiac glycosides binding sites. It may be present in human tissues in four different isoforms (α1, α2, α3, α4 -- found only in testicles). The beta-subunit is responsible for delivery and insertion of alpha one in cell membranes and has three distinct isoforms in humans (β1, β2, β3) ^[@ref-8]--\ [@ref-10]^. NKA subunits are variably expressed in different human tissues ^[@ref-11]^. Changes in the relative expression between different isoforms are associated with a number of pathological processes including malignant transformation ^[@ref-12],\ [@ref-13]^. Both down- and up-regulation of alpha- and beta- subunits were shown in solid tumors of different origin ^[@ref-14]--\ [@ref-19]^.

In the present study, we analyzed public breast cancer expression profiles made using Affymetrix Human Genome U133 Plus 2.0 Array (NCBI GEO database ^[@ref-20]^, accession [GSE65194](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65194)) for the expression of alpha subunits of NKA. We found abnormalities in *ATP1A1* (coding α1-subunit) and *ATP1A2* (coding α2-subunit) expression ( [Table 1](#T1){ref-type="table"}) in breast cancer samples relative to their expression in normal breast tissue. *ATP1A1* was overexpressed approximately 1.5 times in all groups of breast cancer samples (p\<0.05). Coincidently, *ATP1A2* expression decreased by more than 2 times (p\<0.05). There were no differences observed in the expression of *ATP1A3* (coding α3-subunit).

###### NKA genes expression in breast cancer samples relative to normal breast tissue.

  -------------------------------------------------------------------------------------
  Breast cancer\   Lum A             Lum B             Her2              TNBC
  group                                                                  
  ---------------- ----------------- ----------------- ----------------- --------------
  *ATP1A1*         1.53\             1.38\             1.66\             1.44\
                   (0.009016)        (0.04454)         (0.005926)        (0.015725)

  *ATP1A2*         -2.49\            -2.52\            -2.78\            -2.87\
                   (1.85·10 ^-07^)   (8.50·10 ^-09^)   (5.48·10 ^-08^)   (2.08·10-11)

  *ATP1A3*         -1.05\            1.03\             -1.04\            -1.04\
                   (0.429089)        (0.308298)        (0.768041)        (0.527878)
  -------------------------------------------------------------------------------------

Methods
=======

Preanalytical procedures consisted of a robust multichip analysis (RMA) algorithm ^[@ref-21]^, including background correction, probe set signal integration, and quantile normalization. For this purpose, we used Expression Console 1.4 software (Affymetrix, Inc. USA). We utilized Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) to analyze the obtained CHP files and to detect differentially expressed genes using one-way between subjects ANOVA. Array data for 41 triple negative samples (TNBC group), 30 Her2-positive (Her2 group), 30 Luminal B (Lum B group), 29 Luminal A (Lum A group) breast cancer samples and 11 normal breast tissue samples were investigated.

Conclusions
===========

Using a public microarray dataset we found abnormalities in the expression of *ATP1A1* and *ATP1A2* in breast cancer samples. This may correlate with digitalis anticancer activity, but requires additional research. We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer.

Data and software availability
==============================

Raw data for [Table 1](#T1){ref-type="table"} are available at:

<https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE65194&format=file> ^[@ref-22]^.

Expression Console 1.4 software and Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) are available after free customer registration at:

<http://www.affymetrix.com/support/technical/software_downloads.affx>.
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I think the analysis is appropriate to examine the relative expression of the *ATP1A1*and *ATP1A2* among different breast cancer cells. The data analysis is standard and appropriate. One helpful thing is to validate the findings in other breast cancer expression datasets beyond this discovery dataset. Another relevant thing is whether the abnormal expression of these genes are associated with varying clinical outcomes.
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Over the past years several papers were published concerning prognostic role of *ATP1A1* expression in hepatocellular carcinoma, lung cancer, and esophageal cancer. The authors of the present study show that increased expression of *ATP1A1* observed at all breast cancer phenotypes compared to normal tissue.

I would like to note that the authors studied gene expression only, but did not appreciate the immunohistochemical (IHC) changes in the content of gene products. In the absence of data of the IHC expression of *ATP1A1*, it is desirable to represent the differences in gene expression of *ATP1A1* compared to referent genes for membrane transporters ( [http://bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-7-29](https://protect-eu.mimecast.com/s/6LQhBxrLYHx) ). Given a sufficiently large number of patients included in the study, it is interesting to evaluate the prognostic and predictive value of these findings. But I can conclude that this article is interesting for medical oncologists and molecular biologists.
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